Supernus Pharmaceuticals, Inc. (SUPN)
44.05
+0.31
(+0.71%)
USD |
NASDAQ |
Sep 02, 16:00
44.05
0.00 (0.00%)
After-Hours: 17:06
Supernus Pharmaceuticals Research and Development Expense (TTM) : 124.20M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 124.20M |
| March 31, 2026 | 116.76M |
| December 31, 2025 | 104.15M |
| September 30, 2025 | 104.86M |
| June 30, 2025 | 104.43M |
| March 31, 2025 | 108.40M |
| December 31, 2024 | 106.38M |
| September 30, 2024 | 101.08M |
| June 30, 2024 | 94.68M |
| March 31, 2024 | 92.88M |
| December 31, 2023 | 89.14M |
| September 30, 2023 | 83.47M |
| June 30, 2023 | 79.85M |
| March 31, 2023 | 71.55M |
| December 31, 2022 | 71.09M |
| September 30, 2022 | 70.79M |
| June 30, 2022 | 68.62M |
| March 31, 2022 | 74.31M |
| December 31, 2021 | 72.87M |
| September 30, 2021 | 71.53M |
| June 30, 2021 | 71.41M |
| March 31, 2021 | 71.90M |
| December 31, 2020 | 71.66M |
| September 30, 2020 | 76.02M |
| June 30, 2020 | 76.82M |
| Date | Value |
|---|---|
| March 31, 2020 | 72.14M |
| December 31, 2019 | 69.10M |
| September 30, 2019 | 79.15M |
| June 30, 2019 | 82.63M |
| March 31, 2019 | 85.70M |
| December 31, 2018 | 89.21M |
| September 30, 2018 | 75.54M |
| June 30, 2018 | 68.10M |
| March 31, 2018 | 58.88M |
| December 31, 2017 | 49.58M |
| September 30, 2017 | 46.66M |
| June 30, 2017 | 41.54M |
| March 31, 2017 | 41.83M |
| December 31, 2016 | 42.79M |
| September 30, 2016 | 38.98M |
| June 30, 2016 | 40.24M |
| March 31, 2016 | 36.01M |
| December 31, 2015 | 29.14M |
| September 30, 2015 | 25.46M |
| June 30, 2015 | 20.99M |
| March 31, 2015 | 18.79M |
| December 31, 2014 | 19.59M |
| September 30, 2014 | 19.22M |
| June 30, 2014 | 18.34M |
| March 31, 2014 | 17.20M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Indivior Pharmaceuticals, Inc. | 53.00M |
| Pfizer Inc. | 10.82B |
| Amphastar Pharmaceuticals, Inc. | 79.43M |
| Collegium Pharmaceutical, Inc. | -- |
| Bristol Myers Squibb Co. | 9.548B |